Homocysteine, brain natriuretic peptide and chronic heart failure: a critical review

Wolfgang Herrmann, Markus Herrmann, Jacob Joseph, Suresh C Tyagi

Department of Clinical Chemistry and Laboratory Medicine/Central Laboratory, University Hospital, Saarland University, Homburg/Saar, Germany.

Clinical chemistry and laboratory medicine : CCLM / FESCC. 02/2007; 45(12):1633-44. DOI: 10.1515/CCLM.2007.360

Abstract

Chronic heart failure (CHF) is a major public health problem causing considerable morbidity and mortality. Recently, plasma homocysteine (Hcy) has been suggested to be significantly increased in CHF patients. This article reviews the relation between hyperhomocysteinemia (HHcy) and CHF. Clinical data indicate that HHcy is associated with an increased incidence, as well as severity, of CHF. In addition, Hcy correlates with brain natriuretic peptide (BNP), a modern biochemical marker of CHF, which is used for diagnosis, treatment guidance and risk assessment. Animal studies showed that experimental HHcy induces systolic and diastolic dysfunction, as well as an increased BNP expression. Moreover, hyperhomocysteinemic animals exhibit an adverse cardiac remodeling characterized by accumulation of interstitial and perivascular collagen. In vitro superfusion experiments with increasing concentrations of Hcy in the superfusion medium stimulated myocardial BNP release independent from myocardial wall stress. Thus, clinical and experimental data underline a correlation between HHcy and BNP supporting the role of HHcy as a causal factor for CHF. The mechanisms leading from an elevated Hcy level to reduced pump function and adverse cardiac remodeling are a matter of speculation. Existing data indicate that direct effects of Hcy on the myocardium, as well as nitric oxide independent vascular effects, are involved. Preliminary data from small intervention trials have initiated the speculation that Hcy lowering therapy by micronutrients may improve clinical as well as laboratory markers of CHF. In conclusion, HHcy might be a potential etiological factor in CHF. Future studies need to explore the pathomechanisms of HHcy in CHF. Moreover, larger intervention trials are needed to clarify whether modification of plasma Hcy by B-vitamin supplementation improves the clinical outcome in CHF patients.

Comments on this publication

ResearchGate members can add comments. Sign up now and post your comment!

Similar publications

Check out other publications that might be interesting for you.

The Cardiac Effects of Prolonged Vitamin B(12) and Folate Deficiency in Rats
Authors: Omid Taban-Shomal, Heiko Kilter, Alexandra Wagner, Heike Schorr, Natalia Umanyska, Ulrich Hüner, Michael Böhm, Wolfgang Herrmann, Markus Herrmann
Cardiovascular toxicology. 04/2009;

"In the recent past, hyperhomocysteinemia (HHcy) has been linked to chronic heart failure. Folate and vitamin B12 deficiencies are the common causes of HHcy. The impact of these vitamins on..."

Hyperhomocysteinemia in patients with symptomatic chronic heart failure: prevalence and prognostic importance--pilot study
Authors: Marek Naruszewicz, Ewa A Jankowska, Robert Zyminski, Hanna Bukowska, Barbara Milo, Waldemar Banasiak, Piotr Ponikowski

"BACKGROUND: Patients with chronic heart failure (CHF) may be particularly susceptible to unfavorable effects of hyperhomocysteinemia (HHcy). The aim of this study was to assess the prevalenc..."

Value of brain natriuretic peptides in primary care patients with the clinical diagnosis of chronic heart failure
Authors: Peter Kijfer, Peter Buser, Burkhardt Seifert, Paul Eme Borg, Ingrid Glurich, Richard A Dart
Scandinavian cardiovascular journal : SCJ. 03/2009;

"Introduction. Brain natriuretic peptide (BNP) and N-Terminal pro natriuretic peptide (NT-proBNP) are widely used biomarkers in the diagnosis and follow-up of congestive heart failure (CHF)..."

Keywords

BNP 43%
CHF 100%
Homocysteine 29%
natriuretic peptide 27%
speculation 18%
superfusion 13%
has been shown to affect BNP levels in some studies and the diagnostic value o...

Management of L-Dopa related hyperhomocysteinemia: catechol-O-methyltransferase (COMT) inhibitors or B vitamins? Results from a review

Authors: Stefano Zoccolella, Giovanni Iliceto, Michele deMari, Paolo Livrea, Paolo Lamberti


"In recent years, L-Dopa treatment has been indicated as an acquired cause of hyperhomocysteinemia (HHcy). The mechanism underlying L-Dopa-related HHcy is the O-methylation of the drug cataly..."

Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.